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Latin America has experienced two of the largest cholera epidemics in modern history; one in
1991 and the other in 2010. However, confusion still surrounds the relationships between
globally circulating pandemic Vibrio cholerae clones and local bacterial populations. We used
whole-genome sequencing to characterize cholera across the Americas over a 40-year time
span. We found that both epidemics were the result of intercontinental introductions of
seventh pandemic El Tor V. cholerae and that at least seven lineages local to the Americas are
associated with disease that differs epidemiologically from epidemic cholera. Our results
consolidate historical accounts of pandemic cholera with data to show the importance of local
lineages, presenting an integrated view of cholera that is important to the design of future
disease control strategies.
C
holera is an acute intestinal infection that
leads to a rapid and severe dehydrating
diarrhea, and is caused by serogroup O1
and O139 Vibrio cholerae. The global disease
burden of cholera is estimated to be between
1.3 and 4 million cases a year with 21,000 to
143,000 deaths (1). The current seventh pandemic
(7P) of cholera began in 1961 and is attributed to
a V. cholerae O1 biotype El Tor lineage, which is
different from the Classical biotypeV. choleraeO1
thought to be responsible for previous pandemics.
Aside from being a prominent human pathogen,
exploratory analyses have demonstrated since
the 1970s that V. cholerae is an integral member
of many coastal, estuarine, and brackish water
ecosystems, as are other Vibrio species, in which
it is often associated with copepods and zoo-
plankton (2). Accordingly, a view of V. cholerae
epidemiology emerged in the following decades,
which posits that locally evolving, but globally
distributed, V. cholerae populations are respon-
sible for cholera outbreaks, which occur when
climatic or environmental stimuli provide favor-
able bacterial growth conditions in these environs
(3, 4). This perception has had profound effects
on all levels of global public health; cholera is
now considered to be ineradicable because its
etiological agent is ubiquitous in aquatic eco-
systems (3, 5).
Despite advances in our understanding of the
global epidemiology of cholera, we still face un-
answered fundamental questions about the rela-
tionships between local and global V. cholerae
populations. Latin America presents a notable
opportunity to investigate these relationships.
Although this region has local foci of endemic
V. cholerae, such as on the Gulf Coast of the
United States and Mexico (6), pandemic chol-
era was absent from Latin America for nearly
100 years. In January 1991, a cholera outbreak
occurred along the coast of Peru and spread
rapidly to nearly every country in Latin America,
causing 1.2million disease cases and 12,000 deaths
by 1997 (7). More recently, pandemic cholera was
introduced into Haiti (8), where the resultant
epidemic has affected more than 797,000 people
and caused over 9400 deaths (9). In response to
these two large-scale epidemics, regional and
national surveillance systems in Latin America
were hyperalert for cholera outbreaks, and as a
result, their sampling framework captured a
diverse collection of V. cholerae during both
epidemic and interepidemic periods (10, 11).
Coupling these precise epidemiological data,
which describe the beginning of the epidemic, to
increased samplingwithin Latin America, allows
studieswithin this region to offer unprecedented
opportunities to address the relationships be-
tween local populations and globally circulating
pandemic lineages of V. cholerae.
The relationships between these bacterial pop-
ulations have been difficult to characterize until
now, primarily due to the molecular methods
used to assess the relatedness of V. cholerae
isolates to one another (10, 12–14). Inconsistency
in applying and interpreting results generated
using these methods, such as the use of different
restriction enzymes for pulsed-field gel electro-
phoresis and ribotyping, and the lack of stan-
dardized nomenclatures, has further complicated
comparisons between studies. However, it is pos-
sible now to unify these results by using whole-
genome sequencing.
To examine the relationship betweenV. cholerae
lineages in Latin America, we sequenced a collec-
tion of 252 isolates. Phylogenetic analysis showed
that 164 strains were of the 7P El Tor (7PET)
cholera lineage and 88 were strains distinct from
7PET (collectively referred to as non-7PET) (15).
This collection is geographically and temporally
broad, and includes representative isolates from
14 countries spanning 1974 to 2014, including pre-
epidemic, epidemic (isolated and typed during
the 1991 and Haitian epidemics), and interepi-
demic periods. Critically, this collection includes
serogroup O1 and non-O1 isolates, both clinical
and environmental isolates (figs. S1 to S3 tables
S1 to S3, and supplementary text note 1), isolates
typed by early molecular approaches (table S4)
(11, 12), and several key additional 7PET iso-
lates from Africa [see companion analysis of
Weill et al. (16)].
We placed these isolates into a phylogenetic
framework, and determined the evolutionary
relationships between lineages in Latin America.
A global phylogeny, comprising a total of 665
isolates, revealed a marked diversity of V. cholerae
lineages present in this region (Fig. 1 and figs. S2
and S3). Representative isolates from both the
1991 and 2010 epidemics clustered within the
7PET lineage (table S4). The phylogeny also re-
vealed that isolates sampled in different years,
and in some cases across multiple countries, com-
prise 11 lineages in Latin America (Fig. 1 and
fig. S4). These lineages include ClassicalV. cholerae
isolated fromMexico during themid-1990s, as well
as several V. cholerae O1 local lineages, such as the
Gulf Coast lineage (17), or those containing isolates
of Mx1 to Mx3 ribotypes (MX-1 to MX-3 lineages)
described in Mexico (11). The Tucumán variant
from Argentina (18) and the Amazonia variant
from Brazil (19) form a single lineage, named
Endemic Latin American 1 (ELA-1), in which these
isolates remain clearly separated phylogenetically
by their country of origin (Fig. 1A and fig. S2).
Although 7 of the 18 samples sequenced from the
Tucumán and other regions of Argentina belong
toELA-1, the other samples are distributed among
five other lineages. More than 30 additional iso-
lates sampled across Latin America do not belong
to any previously known lineage and comprise at
least eight different serotypes (fig. S5 and table S2).
Local V. cholerae O1 lineages in Latin America
harbor awide range of genetic determinants that
are associatedwith pandemic disease (figs. S6 and
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S7 and tables S2 and S3). For instance, the genes
encoding the bipartite cholera toxin (ctxAB), the
primary virulence determinant of cholera borne
by the lysogenic CTXϕ bacteriophage, are present
in several isolates from the Gulf Coast lineage and
the MX-2 lineage (fig. S7 and tables S2 and S3).
Typing based on the ctxB locus revealed that these
lineages harbor different variants of the cholera
toxin. Several isolates unaffiliated with lineages
sampled from Argentina and the U.S./Mexican
Gulf Coast also harbor ctxAB. Notably, the genes
encoding the toxin co-regulated pilus (TCP), which
allows V. cholerae to colonize the human intestine
successfully, are present in all ELA-3, Gulf Coast,
andMX-2 isolates, whether or not they are CTXϕ+
(fig. S7 and tables S2 and S3). The presence of TCP
(if expressed) confers upon CTXϕ-negative strains
the potential to be infected and lysogenized by
CTXϕ to become cholera toxin producers.
Our results support previous descriptions of
isolates from the Classical lineage in Mexico
between 1995 and 1997 (20, 21). This finding is
notable because it was thought that this biotype
had disappeared, globally, in the late 1980s (20).
A recent study in Thailand, however, recovered
Classical strains isolated as late as 2000 (22),
indicating that this lineage persisted longer
than previously thought. It has been proposed
that Classical cholera isolates were present in
Mexico more than a decade earlier and persisted
there until the mid-1990s (21) because of a single
case, imported into theUnited States fromCancún,
Mexico, in 1983 (23, 24). This isolate was subse-
quently shown to be amember of the Gulf Coast
lineage by ribotyping and electrophoretic typing
(ET) (23–25). Our phylogenetic data show that
Classical biotype isolates in Mexico in the mid-
1990s are part of the Classical lineage, and not
derived from the Gulf Coast lineage (Fig. 1 and
fig. S2).
To understand better the relationships within
the 7PET lineage, we calculated a robust maxi-
mumlikelihoodphylogeny from518 7PETgenomes.
We detected a strong temporal signal, which
allowed us to estimate dated phylogenies (Fig. 2
and fig. S8). These data show that the Latin
American cholera epidemics were the result of
multiple intercontinental introductions (Fig. 2),
whichwe refer to as LAT (Latin American transmis-
sion) 1 to 3. Our phylogeny reveals that two in-
dependent intercontinental introductions of 7PET
V. cholerae into Latin America contributed to the
1991 epidemic (Fig. 2). Themajor epidemic clone
during the 1991 epidemic is represented by the
LAT-1 sublineage, corresponding phylogeneti-
cally to the previously described 7PET pandemic
wave 1 isolates that form the West-African South
American (WASA) lineage (26); these were origi-
nally typed as serotype Inaba, ribotype 5, and ET 4
(table S4) (12).We identified a frame-shiftmutation
at position 165 in the wbeT gene, consistent with
the Inaba serotype in this lineage (table S1).
LAT-1 isolates carry the El Tor variant of ctxB
(ctxB3). The direct ancestors of LAT-1 in our phy-
logeny are isolates from Western and Central
Africa (Angola, Cote d’Ivoire, Sao Tome) from
the late 1980s. These African isolate genomes
and the LAT-1 sublineage are separated by only
13 nonrecombinant single-nucleotide polymor-
phisms (SNPs). Further support for an African an-
cestry is the placement of African isolates (Uganda
1992, Nigeria 1997) within the LAT-1 sublineage.
Several lines of evidence suggest that this intro-
duction occurred close in time to the recorded
start of the epidemic. First, our time-resolved
phylogenies date this introduction to between
1985 and 1989, and the most recent common an-
cestor of LAT-1 isolates to 1989 (Fig. 2A). Second,
our data show that genetic features that define
the LAT-1 sublineage—the VSP-II gene variants
(insertion betweenVC_0510 andVC_0516) and the
WASA-1 genomic island—were acquired succes-
sively and in Africa during the late 1980s prior to
this introduction (Fig. 2A and fig. S9). Moreover,
Western Africa experienced cholera outbreaks
immediately before the Peruvian epidemic (fig.
S10). Tests for vibriocidal antibodies in stored sera
from Lima, Peru, in 1990 indicate that V. cholerae
was not present at this time (25 ). LAT-1 isolates
were isolated inMexico until 2010 (Fig. 2C). The
more recent LAT-1 isolates collected between
2004 and 2010 in Mexico harbored a truncated
CTXϕduplication and represent localized adapta-
tions of these 7PET strains (27) (Fig. 2A).
The second clone introduced into Latin America
in 1991 was described as serotype Ogawa, ribotype
6a, ET3 (12, 13), and resistant to furazolidone,
sulfisoxazole, and streptomycin (13). This clone
was first detected in a mountainous village near
Mexico City, Mexico, in June 1991 and is believed
to have been imported via coca smugglers using
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Fig. 1. Multiple lineages of V. cholerae are present in Latin America. (A) Maximum
likelihood phylogeny of 148 V. cholerae genomes. Local lineages present in Latin America are
highlighted. The 7PET lineage is shown as a collapsed triangle. Four 7PET genomes
(reference genome N16961, and examples of LAT-1 to -3) were used as representatives of the 518
7PETgenomes in this study. The scale bar denotes substitutions per variable site. The hash mark
denotes a branch that was artificially shortened; the full tree is shown in figs. S2 and S3.
(B) Geographical distribution of selected local V. cholerae lineages in Latin America. The size of
the circle denotes the number of genomes analyzed from that area. Only isolates annotated
with explicit geographic information are shown. (C) Temporal distribution of genomes sampled
from V. cholerae lineages present in Latin America. The size of the circle scales with the number
of genomes in our study for each lineage.
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nearby private airstrips (28). This clone subse-
quently spread throughout Central America (13).
After 1993, this was the major clone circulating
inMexico, where it persisted until 2000 (Fig. 2C)
(11). Our phylogeny shows that the introduction
of this second sublineage (LAT-2) occurred between
1987 and 1989, making this event concurrent
with that of the LAT-1 introduction (Fig. 2A). The
distinctive drug resistance profile of the LAT-2
sublineage was linked to the presence of a ge-
nomic island (GI-15) (Fig. 2A and figs. S9 and
S11). GI-15 harbors the genes responsible for
streptomycin (aadA) and sulfisoxazole (sul1) re-
sistance. With the exception of a few sporadic
isolates, LAT-1 isolates were pan-susceptible to
antimicrobials, and all lacked GI-15. The most
closely related isolates to those of LAT-2 are those
that were collected in South and Southeast Asia,
Western Asia (Lebanon), and Eastern Europe
(Romania) (Fig. 2A and table S1), many of which
also harbor GI-15. These globally circulatingwave
2 isolates, including the LAT-2 sublineage, also
harbor ctxB1 (fig. S9) with CTXϕ integrated into the
smaller chromosome. Thus, the previously iden-
tified 7PET lineage harboring ctxB1 in Mexico (20)
was not a local lineage, but was derived from the
LAT-2 introduction. Our phylogeny indicates that
this lineage originated from South or Southeast
Asia (Fig. 2), fromwhere it radiated globally. How-
ever,we cannot rule out that the introduction into
Mexico came via secondary site(s) and not di-
rectly from Asia (Fig. 2, A and B).
The third introduction (LAT-3) involved the
import of a South Asian strain into Haiti in 2010
and has been well documented (8, 29, 30). The
Haitian clone has been imported into surrounding
countries, including Cuba, the Dominican Republic,
the United States, andMexico (31, 32) (Fig. 2). An
outbreak in 2013 within the Mexican region of
Hidalgo was suspected to be the result of an im-
port of the Haitian clone (32, 33). Our phylogeny
indicates that these isolates descended from the
Haitian (LAT-3) sublineage (Fig. 2) and share
key genomic features, including the ctxB7 var-
iant and a characteristic deletion within VSP-II
(DVC_0495-VC_0512) (29) (fig. S9).
Combined, we observe that V. cholerae line-
ages are associatedwith three distinct patterns of
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Fig. 2. Intercontinental introductions of seventh pandemic V. cholerae
El Tor into Latin America. (A) Time-scaled maximum likelihood phylogeny of
518 7PET genomes. Inner rings denote time in years. Colored branches
correspond to sublineages introduced into Latin America and are labeled LAT-1
to -3. The geographic location of the isolates corresponds to the colored block
in the GEO legend. Key genomic features that define lineages are shown in
gray in outer bands. The introduction events are numbered on the outside of
the circle. (B) Intercontinental introductions of seventh pandemic cholera
into Latin America. Introductions are indicated by solid lines. The direct
introduction of the LAT-2 sublineage from South Asia or China or introduction
via Eastern Europe is uncertain and is denoted by dashed lines. The year
of the first appearance of these lineages in Latin America is indicated.
(C) Temporal distribution of the number of cases reported to the World
Health Organization (WHO) in Latin America and number of genomes
sampled in this study per LATsublineage.The size of the circle scales with the
number of genomes in our study for each sublineage.
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diarrheal disease within Latin America. First, there
are lineages responsible for sporadic cases or
limited outbreaks, in which secondary infections
are rare or nonexistent (Fig. 1C) (11). Second,
lineages that occupy long-term environmental
reservoirs (such as the Gulf Coast lineage) cause
illness over longer periods of time and across
larger geographic areas (Fig. 1C and fig. S4). The
third pattern, caused by pandemicV. cholerae, is
visibly distinct. Pandemic lineages are responsible
for massive, explosive epidemics that occur over
short periods of time. The epidemiological distinc-
tion between local and pandemic lineages is stark—
nearly 20,000 cases per week were seen at the
beginning of the 1991 epidemic in Peru (28), and
more than250,000 caseswere seenover 6months
at the beginning of the 2010 Haitian epidemic.
By contrast, only 65 infections reported over a
20-year period in the USA were associated with
the Gulf Coast reservoir (34). We expand upon
these definitions in supplementary text note 2.
We show conclusively that both historical cholera
epidemics within Latin America were the result
of intercontinental introductions of globally circu-
lating 7PET lineages and were not derived from
indigenous local lineages. These data (i.e., the
introduction of LAT-1 from Africa) also do not
support the hypothesis that El Niño was respon-
sible for the introduction of cholera in Peru in
1991 by potentiating the long-distance transport
of aquatic pathogens fromAsia through a biological
corridor (35) or due to a surge in preexisting local
lineages (36,37) (Figs. 1and2).Our data are instead
consistent with descriptions of how cholera was
introduced into Haiti in 2010 (i.e., through carriers
or patients from endemic regions) (8, 30). We have
shown that over a 30-year span, several local
lineages are present at relatively constant levels
(Fig. 1C). This underlines that local and pandemic
lineages exhibit different epidemiological behav-
iors, andmay occupy different ecological niches in
Latin America.
We show that there are local foci of diverse
V. cholerae lineages that cause sporadic out-
breaks across Latin America. Local lineages share
many characteristics with pandemic clones, such
as being toxigenic and of serogroup O1 (table S3).
Disease caused by these lineages would thus be
defined as cholera by both the World Health
Organization (38) and U.S. Centers for Disease
Control and Prevention (39). However, these local
lineages showmarkedly different patterns of dis-
ease to that of the 7PET pandemic V. cholerae
lineage. The potential of a V. cholerae isolate to
cause disease is best understood by studying its
genomics, whether by whole-genome sequenc-
ing or a polymerase chain reaction–based typing
scheme, as well as considering clinical symptoms,
epidemiological context, and basic pheno- and
serotyping data.
In this study,wehave unified previous accounts
of cholera within Latin America into a cohesive
genomic framework that correctly emphasizes the
relative contributions of different bacterial line-
ages to this diarrheal disease. An appreciation of
the differences between pandemic and local line-
ages should inform the design of disease control
strategies in Latin America.Measured and graded
public health responses could be designed based
on an understanding of which lineages are re-
sponsible for outbreaks of cholera. V. cholerae
lineages can be prioritized as public health con-
cerns if they deviate from patterns associated
with local lineages.
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 populations remain distinct. Now, Weill Vibrioeradication measures apparently fruitless. Nevertheless, local and global 
, is considered to be ubiquitous in water systems, making the design ofVibrio choleraeThe cholera pathogen, 
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